Avenue Therapeutics Announces Upcoming Investor Engagements
MIAMI, Sept. 03, 2024 — Avenue Therapeutics, Inc. (Nasdaq: ATXI) is preparing for several significant investor conferences. This effort underscores Avenue's dedication to enhancing treatments for neurologic diseases. Alexandra MacLean, M.D., the Chief Executive Officer of the company, will represent Avenue at these key events.
Key Conference Details
Avenue Therapeutics is set to participate in the following conferences:
H.C. Wainwright 26th Annual Global Investment Conference
Date: September 9, 2024
Format: Company Presentation and 1x1 Meetings
Lake Street Capital Markets BIG8 Conference
Date: September 12, 2024
Format: 1x1 Meetings
The presentation at the H.C. Wainwright conference will be available for on-demand viewing starting at 7:00 a.m. ET on September 9, 2024. This is a fantastic opportunity for investors to gain insights into Avenue Therapeutics' innovative research and strategic direction.
About Avenue Therapeutics
Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialized pharmaceutical company focused on developing and commercializing advanced therapies for neurologic conditions. Currently, the company is concentrating on three major projects: AJ201, which targets spinal and bulbar muscular atrophy; BAER-101, a selective GABAA ?2, ?3 receptor positive allosteric modulator designed for central nervous system diseases; and IV tramadol, aimed at managing acute postoperative pain in medically supervised settings.
Founded by Fortress Biotech, Inc. (Nasdaq: FBIO), Avenue Therapeutics is strategically based in Miami, FL. Their innovative approach and commitment to enhancing patient care distinguish them within the pharmaceutical industry.
Contact Information
For any inquiries, please reach out to Jaclyn Jaffe at Avenue Therapeutics, Inc. You can contact her at (781) 652-4500 or via email at ir@avenuetx.com.
Frequently Asked Questions
What is Avenue Therapeutics focused on?
Avenue Therapeutics is dedicated to developing therapies for neurologic diseases, emphasizing innovative treatment solutions.
Who will represent Avenue at the upcoming conferences?
Alexandra MacLean, M.D., the CEO of Avenue Therapeutics, will be the representative for the company at these events.
What are the dates for the investor conferences?
The H.C. Wainwright conference is scheduled for September 9, 2024, while the Lake Street Capital Markets conference will take place on September 12, 2024.
How can I contact Avenue Therapeutics for more information?
For more information, you can reach Jaclyn Jaffe at (781) 652-4500 or via email at ir@avenuetx.com.
What innovative projects is Avenue Therapeutics working on?
Avenue is currently developing AJ201, BAER-101, and IV tramadol, each targeting various aspects of neurologic conditions.